Intercept Pharmaceuticals

Ticker ICPT

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

201-500 Employees
Based in New York City, New York

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia.

Visit website

Social Media Links

REPORT RATINGS

4.7 / 5.0 (121)

Intercept Pharmaceuticals reports have an aggregate usefulness score of 4.7 based on 121 reviews.

Intercept Pharmaceuticals

Most Recent Annual Report

MOST RECENT 2022 Annual Report and Form 10K

View PDF View Form 10K (HTML)

Intercept Pharmaceuticals does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.

Please fill out the form below and click "Place Order" to complete your order.